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A B S T R A C T
We sought to determine the proportion of our admitted patients in terminal phase of ilness who recieved some kind of
active oncological therapy. We conducted a pilot study on the records of patients who died in the University Hospital. We
assessed the percentage of mortality, a therapeutic approach in terms of treating the underlying disease, and access to
palliative treatment. Of 2097 patients hospitalized in the UHC Rijeka Department of Radiation Therapy and Oncology
during 2010 and 2011, 44 pts died which accounts for 2.1%. The most common primary sites of cancer in patients who
died in our Department were the lungs and then the breast. Ten (22.7%) patients were admitted exclusively to receive pal-
liative care, while others (34–77.3%) were admitted for planned active chemo- and/or radiotherapy administration. With-
in three months before death, 18 (40.9%) patients underwent chemotherapy treatment. The number of patients hospital-
ized due to providing palliative care is extremely low, which could indicate a good supply of out-patient treatment of
cancer patients in the terminal stage of the disease. However, concerned about the high percentage of patients who tried to
provide oncology treatments in the three months before his death. The percentages referred to in their daily work is still
guided by the principles of healing »to the end« and thus we plunge into the realm disthanasia.
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Introduction
The number of patients receiving chemotherapy at
the end of their life is increasing1. However, this raises
questions over the appropriateness of their treatment,
therapy toxicity to such patients, and finally costs to soci-
ety. It has been shown that the U.S. spend millions of dol-
lars more on chemotherapy treatment for cancer pa-
tients than on therapies for treating cardiovascular or
diabetes diseases2–4. According to ESMO reports from
2005, the proportion of patients starting a chemotherapy
regimen within 3 months and 1 month before death was
67% and 25%, respectively5. The administration of che-
motherapy at the end of life was especially frequent in
patients with pancreatic, breast and ovarian cancer5. Ac-
cording to some earlier records, chemotherapy in the last
3 months of life was most frequently given to patients
with hematologic cancers (45%)6. The ESMO reports for
2008–2009. showed the frequency of chemotherapy use
within 2 months before death to be as high as 48% and
within 1 month before death no less than 29%6.
The study from 2006 showed that 39%, 28% and 21%
of patients with non-small lung cancer received first-line,
second-line, and third-line chemotherapy, respectively3,7.
This reveals a large proportion, i.e. no less than 43% of
patients receiving chemotherapy within 1 month before
death7, while 20% of them receive chemotherapy within
2 weeks before death7. Other literature data, however,
show a smaller proportion of patients receiving chemo-
therapy within 3 months before death, of 11, 26 and
33%4,6. Both clinicians and researchers conclude that
providing chemotherapy to cancer patients at the end of
life is after all a priority for patients of younger age and
for chemo-sensitive tumors7. It has also been shown that
a large proportion, ranging from 1/3 to no less than a half
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of patients die in the hospital, which is partly due to the
provision of chemotherapy that prolongs life without a
desired quality, and even exerts harmful effects and
brings terminal cancer patients into such a state that
they cannot be discharged from hospital8,9. Cyclophos-
phamide, doxorubicin and vincristine lead to prolonged
inpatient stays and the development of sepsis in already
immuno-compromised patients10. Although it has been
found that chemotherapy has no value for elderly pa-
tients and those with advanced metastatic disease, the
percentage of 6–10% of patients receiving chemotherapy
in their last week of life still persists11. The ESMO data
from 2005 showed that 24% of patients got admitted to
hospital due to chemotherapy toxicity5. However, unfavor-
able patient outcomes were also found among palliative
chemotherapy recipients12,13. In addition, biotherapy given
to terminal patients was shown not to differ from chemo-
therapy given to such patients7. More detailed communi-
cation with patients is therefore needed to inform them
about the consequences of chemotherapy treatments, out-
come following the administration, and the prognosis.
Palliative radiation therapy is aimed at reducing
symptoms of the disease and alleviating patient’s suffer-
ing. Since the aim of palliative radiation is alleviation of
symptoms (pain, bleeding control, obstruction reduction,
reduction of a tumor mass that causes symptoms, etc.)
rather than a complete destruction of the tumor, the dose
and the number of fractions are smaller compared to rad-
ical radiation therapy. Early and late side effects of radia-
tion will thus be avoided in the population of patients
having a shorter life expectancy. Palliative radiotherapy
is most often used in patients with bone metastases to al-
leviate pain, and then in patients with advanced lung
cancer and inoperable cancer of the head, neck, pelvis,
etc.14. Palliative radiation treatment of brain metastases
is usually indicated when pain and brain edema occurs
and a short-course radiation regimen is used. There are,
however, cases where palliative radiotherapy does not
provide much benefit and in the process of decision-mak-
ing, the decision must be well documented with regard to
patient’s general condition and expected survival14,15.
The aim of our study was to analyze approach to can-
cer patients with end-stage disease at the Radiotherapy
and Oncology Clinic, University Hospital Rijeka, and to
correlate our results (approach) to the results from else-
where in the world.
Matherial and Methods
A pilot study involving medical records of patients
who died in our Clinic over a 2-year period (2010–2011)
was carried out. The study included analysis of the mor-
tality rate and therapeutic approaches in cancer patients
with end-stage disease.
Results
Of 2097 patients hospitalized in the Radiotherapy and
Oncology Clinic, Rijeka University Hospital Center dur-
ing 2010 and 2011, 44 pts died which accounts for 2.1% of
all hospitalized patients. Among descendents, there were
11 (25%) younger than 60 years of age, and 33 (75%)
were older than 60 years of age. There were 26 (59%)
male and 18 (41%) female. The most common primary
sites of cancer were the lungs (40.1% of all patients), and
the breast. Ten (22.7%) patients were admitted exclu-
sively to receive palliative care, while others (34–77.3%)
were admitted for planned active chemo- and/or radio-
therapy administration. Within three months before death,
18 (40.9%) patients underwent chemotherapy treatment,
and 6 patients received chemo and radiotherapy. The
most commonly used chemotherapy regimen was the PE
regimen (cisplatin + etoposide). These patients were not
found to be either of younger age, or that there were any
difference by sex. In the preceding 3 months, 13 (29.5%)
patients received an active chemotherapy, and 2 patients
received biotherapy (erlotinib, sunitinib). After chemo-
therapy administration within 3 months before death, 3
patients were admitted to hospital for symptoms of fe-
brile neutropenia.
In a total of 15 (34.1%) patients, planned palliative ra-
diotherapy was either initiated or completed. Most com-
monly, palliative radiation treatment was given to pa-
tients with lung cancers for the purpose of reducing their
dyspnea. Palliative radiation therapy over the CNS re-
gion ranked second in the frequency of use for patients
with confirmed brain metastases with or without accom-
panying neurologic symptoms. In our Department, ad-
ministration of pain relieving palliative radiotherapy to
patients with confirmed bone metastases ranked third in
frequency.
Conclusion
Over 11 million new cancer cases are diagnosed each
year worldwide16. In about 50% of patients the disease
has already spread at the time of diagnosis17. According
to the World Health Organization, there were 7.6 million
cancer deaths (13% of all deaths) worldwide in 200816.
Most commonly reported are deaths from cancers of the
lung, pancreas, stomach, liver, breast and prostate16,18.
The beginning of life as well as dying and death are is-
sues of primary interest to every society. The increasing
daily use of state-of-the-art technology for the severely ill
or patients at the end of life is the topic of medical, philo-
sophical, theological, legal, sociological, bioethical and
other debates among both numerous professionals and
public media as well19. The task of modern oncology is
not only to prolong life of end-stage patients but also to
improve their quality of life (QoL) and allow, if it’s un-
avoidable, for dignified dying. The use of palliative che-
mo- and radiotherapy has its indications, in emollient
painful symptoms and increasing QoL; otherwise it should
be discontinued when disease progresses into terminal
stadium (about three months before an expected death).
Chemotherapy can produce serious toxicity and there-
fore its administration affects the QoL, and may also
cause premature death13.
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The percentage of patients who died in our Depart-
ment falls within the expected range (data from the de-
veloped countries)18. The number of patients admitted to
receive palliative care only is notably small which might
reflect good outpatient provision of care to cancer pa-
tients in the terminal stage of the disease. However,
there are concerns about a large percentage of patients
for whom anticancer therapy was provided in the last
three months before death, which occasionally lead to
the development of febrile neutropenia. In a study car-
ried out in patients with hormone-resistant prostate can-
cer 32% of patients received chemotherapy within 3
months before death, and adverse events occurred in
25% of patients (neutropenia 18.3%, nausea and vomit-
ing 18%, and febrile neutropenia 13.6%)19. Furthermore,
it was shown that the use of therapy is appropriate for
patients in good general condition (according to the
WHO’s guidelines, not for patients with performance
status 3 and 4), while there is insufficient evidence of the
use of chemotherapy for elderly patients (70–75 years of
age)20. The necessity of caution and good assessment to
whom and when to administer any platinum derivative
has been particularly pointed out20.
The percentage shows that in everyday practice we
are still guided by the principles of treatment ‘to the
end’ and thus we enter the field of dysthanasia. Etymo-
logically, dysthanasia means the undue prolongation of
patient’s agony, suffering and death. With perseverance
in therapy with multiple medications and use of sophisti-
cated technology, when there is no hope for cure, we can
prolong a patient’s life, without providing a benefit to the
patient, but increasing and prolonging the patient’s suf-
fering21,22. Sometimes it is very hard to give exact prog-
nosis, despite assessment of the current spread of the dis-
ease. The doctors, however, must approximately assess
when a patient reaches the end stage of the disease to re-
place the planned short course and aggressive chemo-
therapy treatment with best supportive care15,21. Sup-
portive and palliative care controls symptoms that are
not specific as to etiology of the disease. They may be of
organic, psychological, psychosocial and spiritual origin.
During last days of life, characteristic symptoms usually
occur including dyspnea, pain, nausea, vomiting, anxiety
and restlessness15,22.
The most common signs and symptoms reported in
patients who died in our Clinic included pain, immobility,
constipation, anemia, fever and nutritional deficiency.
Those are classical signs and symptoms of cancer pa-
tients with end stage disease, but the majority of them,
as obvious, received active anticancer therapy23.
Over the past decade, family members play an in-
creasing role when making decisions to withhold active
treatment. Disagreements between physicians and the
family often occur during the decision-making process.
Sometimes, this may even end up in court. Patients and
more often, their families do not understand the disease
process and have unrealistic expectations or believe that
any treatment at the end-stage disease (chemotherapy at
the end of life) is better than receiving none and simply
waiting for death. Anticancer treatments thus are used
to give false hope that it is not all over yet and that death
will not come soon. An open and honest conversation be-
tween the doctor, who is not merely a good clinician but
also one educated in bioethics, and the family will allow
for the best and timely decision-making to withdraw
life-sustaining therapy. Informed consent should include
a fair, both culturally and religiously sensitive communi-
cation that provides an explanation of practices for with-
drawal of life support and information about life expec-
tancy. The ultimate goal is to reduce mental and physical
suffering of the patient (if he or she is conscious), and the
family to a minimum, and to relieve discomforts21,23,24.
However, death education is still not included in the
medical school curriculum, and there is a sort of void
both amongst health care professionals and the lay pub-
lic, since the knowledge on the rights of the dying is still
not required from anyone, for any discipline. Although
each of us will inevitably die, only a few of us get ready
for death or make preparations to die the right way.
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PRISTUP ZBRINJAVANJA TERMINALNIH ONKOLO[KIH BOLESNIKA NA KLINICI ZA
RADIOTERAPIJU I ONKOLOGIJU KBC RIJEKA
S A @ E T A K
Cilj rada bio je ustanoviti pristup onkolo{kim bolesnicima u terminalnoj fazi bolesti na Klinici za radioterapiju i
onkologiju KBC Rijeka. Proveli smo pilot istra`ivanje na dokumentaciji bolesnika koji su preminuli na na{oj Klinici u
razdoblju od 2010–2011. Ispitivali smo postotak mortaliteta, terapeutski pristup u smislu lije~enja osnovne bolesti kao i
pristup palijativnom lije~enju. Unutar navedenog raudoblja hospitalizirali smo 2097 pacijanata od ~ega je njih 44 pre-
minulo {to ~ini 2,1%. Naju~estalije primarno sijelo tumora u umrlih bolesnika na na{oj Klinici, bio je karcinom plu}a, a
potom karcinom dojke. Radi primjene isklju~ivo palijativne skrbi hospitalizirano je 6 (22,7%) bolesnika, dok smo ostale
bolesnike (34–77,3%) hospitalizirali predmijevaju}i primjenu aktivne kemo i/ili radioterapije. U razdoblju od tri mje-
seca pred smrtni ishod, 18 (40,9%) bolesnika je primilo aktivnu kemoterapiju. Broj bolesnika hospitaliziranih poradi
pru`anja palijativne skrbi je izuzetno malen, {to bi moglo upu}ivati na dobru vanbolni~ku opskrbu onkolo{kih boles-
nika u terminalnoj fazi bolesti. Me|utim, zabrinjava visoki postotak bolesnika kojima se poku{ala pru`iti onkolo{ka
terapija u razdoblju od tri mjeseca prije smrti. Navedeni postotak upu}uje da se u svakodnevnom radu jo{ uvijek ruko-
vodimo principima lije~enja »do kraja« i time zalazimo u podru~je distanazije.
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